Introduction: Approximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respond well to endoscopic transurethral resection. However, 70% of these patients experience tumor recurrence. As the tendency for local recurrence and/or progression extends over the lifetime, patients with superficial bladder cancer must undergo life-long surveillance. Combination of cystoscopy and urine cytology is considered the “gold standard” for this surveillance. However, they suffer from drawbacks where cystoscopy is an invasive procedure and urine cytology shows limited ability to detect low grade bladder tumors. Therefore, new non-invasive tests with high sensitivity and specificity that are easy to perform are needed not only for initial dia...
Bladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most pr...
Introduction: Painless hematuria is the presenting symptom in 85–90% of patients with bladder cancer...
Objective: To assess whether epidermal growth factor receptor (EGFR) and survivin immunostaining of ...
AbstractIntroductionApproximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respon...
Introduction: Approximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respond well...
Contains fulltext : 50926.pdf (publisher's version ) (Closed access)Expression of ...
\(\it Background\): Urinary biomarkers have the potential to improve the early detection of bladder...
BACKGROUND: Urinary biomarkers have the potential to improve the early detection of bladder cancer. ...
Urinary biomarkers have the potential to improve the early detection of bladder cancer. Most of the ...
AbstractObjectivePrevious studies have reported that survivin expression is significantly associated...
© 2021 Sugeeta, Sharma, Ng, Nayak and Vasdev. This is an open-access article distributed under the t...
Introduction. The most frequent type of bladder cancer in adults is the one derived from transitiona...
Bladder cancer (BC) is the seventh most common cancer worldwide and its incidence has increased in t...
The costly and burdensome nature of the current follow-up methods in non-muscle-invasive bladder can...
© 2021 Sugeeta, Sharma, Ng, Nayak and Vasdev. This is an open-access article distributed under the t...
Bladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most pr...
Introduction: Painless hematuria is the presenting symptom in 85–90% of patients with bladder cancer...
Objective: To assess whether epidermal growth factor receptor (EGFR) and survivin immunostaining of ...
AbstractIntroductionApproximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respon...
Introduction: Approximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respond well...
Contains fulltext : 50926.pdf (publisher's version ) (Closed access)Expression of ...
\(\it Background\): Urinary biomarkers have the potential to improve the early detection of bladder...
BACKGROUND: Urinary biomarkers have the potential to improve the early detection of bladder cancer. ...
Urinary biomarkers have the potential to improve the early detection of bladder cancer. Most of the ...
AbstractObjectivePrevious studies have reported that survivin expression is significantly associated...
© 2021 Sugeeta, Sharma, Ng, Nayak and Vasdev. This is an open-access article distributed under the t...
Introduction. The most frequent type of bladder cancer in adults is the one derived from transitiona...
Bladder cancer (BC) is the seventh most common cancer worldwide and its incidence has increased in t...
The costly and burdensome nature of the current follow-up methods in non-muscle-invasive bladder can...
© 2021 Sugeeta, Sharma, Ng, Nayak and Vasdev. This is an open-access article distributed under the t...
Bladder cancer (BC), the most frequent malignancy of the urinary system, is ranked the sixth most pr...
Introduction: Painless hematuria is the presenting symptom in 85–90% of patients with bladder cancer...
Objective: To assess whether epidermal growth factor receptor (EGFR) and survivin immunostaining of ...